CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
CureVac宣布在多个地区（包括美国、英国和德国）对辉瑞/BioNTech正在进行的专利诉讼进行最新的审判日期
-
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
-
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation
-
UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024
-
经与Acuitas Therapeutics和解后，针对美国专利诉讼的新审判日期定于2025年3月3日。
-
在德国专利诉讼的背景下，针对EP 3 708 668 B1（分裂的聚A尾技术）有效性的一审决定定于2025年3月25日由欧洲专利局作出。
-
英国针对EP 3 708 668 B1和EP 4 023 755 B1（分裂的聚A尾技术）的知识产权有效性审判于7月10日开始，预计于2024年晚些时候作出判决。